Search

Your search keyword '"Bjørge, Line"' showing total 506 results
Start Over Author "Bjørge, Line"
506 results on '"Bjørge, Line"'

2. Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis

Author

May, Taymaa, Bernardini, Marcus, Lheureux, Stephanie, Aben, Katja KH, Bandera, Elisa V, Beckmann, Matthias W, Benitez, Javier, Berchuck, Andrew, Bjørge, Line, Carney, Michael E, Cramer, Daniel W, deFazio, Anna, Dörk, Thilo, Eccles, Diana M, Friedlander, Michael, García, María Jose, Goode, Ellen L, Hein, Alexander, Høgdall, Claus K, Jensen, Allan, Johnatty, Sharon, Kennedy, Catherine J, Kiemeney, Lambertus A, Kjær, Susanne K, Kupryjańczyk, Jolanta, Matsuo, Keitaro, McGuire, Valerie, Modugno, Francesmary, Paddock, Lisa E, Pejovic, Tanja, Phelan, Catherine M, Riggan, Marjorie J, Rodriguez-Antona, Cristina, Rothstein, Joseph H, Sieh, Weiva, Song, Honglin, Terry, Kathryn L, van Altena, Anne M, Vanderstichele, Adriaan, Vergote, Ignace, Thomsen, Liv Cecilie Vestrheim, Webb, Penelope M, Wentzensen, Nicolas, Wilkens, Lynne R, Ziogas, Argyrios, Jiang, Haiyan, and Tone, Alicia

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Ovarian Cancer, Cancer, Clinical Research, Rare Diseases, 6.4 Surgery, Evaluation of treatments and therapeutic interventions, Humans, Female, Middle Aged, Retrospective Studies, Neoplasm Staging, Ovarian Neoplasms, Cystadenocarcinoma, Serous, Kaplan-Meier Estimate, Ovarian Cancer Association and the Australian Ovarian Cancer Study Group, Clinical Sciences, Surgery, Clinical sciences
Abstract

BackgroundWomen with low-grade ovarian serous carcinoma (LGSC) benefit from surgical treatment; however, the role of chemotherapy is controversial. We examined an international database through the Ovarian Cancer Association Consortium to identify factors that affect survival in LGSC.MethodsWe performed a retrospective cohort analysis of patients with LGSC who had had primary surgery and had overall survival data available. We performed univariate and multivariate analyses of progression-free survival and overall survival, and generated Kaplan-Meier survival curves.ResultsOf the 707 patients with LGSC, 680 (96.2%) had available overall survival data. The patients' median age overall was 54 years. Of the 659 patients with International Federation of Obstetrics and Gynecology stage data, 156 (23.7%) had stage I disease, 64 (9.7%) had stage II, 395 (59.9%) had stage III, and 44 (6.7%) had stage IV. Of the 377 patients with surgical data, 200 (53.0%) had no visible residual disease. Of the 361 patients with chemotherapy data, 330 (91.4%) received first-line platinum-based chemotherapy. The median follow-up duration was 5.0 years. The median progression-free survival and overall survival were 43.2 months and 110.4 months, respectively. Multivariate analysis indicated a statistically significant impact of stage and residual disease on progression-free survival and overall survival. Platinum-based chemotherapy was not associated with a survival advantage.ConclusionThis multicentre analysis indicates that complete surgical cytoreduction to no visible residual disease has the most impact on improved survival in LGSC. This finding could immediately inform and change practice.

Published
2023

3. Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup

Author

Barretina-Ginesta, Pilar, Bennett, Katherine, Berek, Jonathan, Berger, Regina, Bjørge, Line, Boere, Ingrid, Brennan, Donal, Bruchim, Ilan, Chang, Ting-Chang, Chavez Blanco, Adriana, Chen, Xiaojun, Colombo, Nicoletta, Crosbie, Emma, Denys, Hannelore, Duska, Linda, Fruehauf, Filip, Gomez Garcia, Eva Maria, van Gorp, Toon, Grimm, Christoph, Guitmann, Gustavo, Han, Kathy, Hanker, Lars, Harano, Kenichi, Hasegawa, Kosei, Herrington, C Simon, Ip, Philip, Joly, Florence, Khaw, Pearly, Kohn, Elise, Kristeleit, Rebecca, Kroep, Judith, Leary, Alexandra, Lee, Jung-Yun, Lheureux, Stephanie, Liu, Jihong, Mackay, Helen, Mahner, Sven, Mariani, Andrea, McAlpine, Jessica, Mikami, Yoshiki, Mirza, Mansoor Raza, Mukhopadhyay, Asima, Nagao, Shoji, Ng, Joseph, Nogueira-Rodrigues, Angelica, Novák, Zoltán, O'Donnell, Jennifer, Osborne, Sherill, Perez-Fidalgo, J. Alejandro, Romeo Marin, Margarita, Roy Chowdhury, Rahul, Sadozye, Azmat, Safra, Tamar, Scott, Claire, Sehouli, Jalid, Slomovitz, Brian, Tan, David, Taylor, Alexandra, Valabrega, Giorgio, Veneziani, Ana, Verhoeven, Karen, Vetter, Marcus, Wampfler, Julian, Westin, Shannon, Wimberger, Pauline, Zola, Paolo, Creutzberg, Carien L, Kim, Jae-Weon, Eminowicz, Gemma, Allanson, Emma, Eberst, Lauriane, Kim, Se Ik, Nout, Remi A, Park, Jeong-Yeol, Lorusso, Domenica, Mileshkin, Linda, Ottevanger, Petronella B, Brand, Alison, Mezzanzanica, Delia, Oza, Amit, Gebski, Val, Pothuri, Bhavana, Batley, Tania, Gordon, Carol, Mitra, Tina, White, Helen, Howitt, Brooke, Matias-Guiu, Xavier, Ray-Coquard, Isabelle, Gaffney, David, Small, William, Jr, Miller, Austin, Concin, Nicole, Powell, Matthew A, Stuart, Gavin, and Bookman, Michael A

Published
2024
Full Text
View/download PDF

4. Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions

Author

Dareng, Eileen O., Coetzee, Simon G., Tyrer, Jonathan P., Peng, Pei-Chen, Rosenow, Will, Chen, Stephanie, Davis, Brian D., Dezem, Felipe Segato, Seo, Ji-Heui, Nameki, Robbin, Reyes, Alberto L., Aben, Katja K.H., Anton-Culver, Hoda, Antonenkova, Natalia N., Aravantinos, Gerasimos, Bandera, Elisa V., Beane Freeman, Laura E., Beckmann, Matthias W., Beeghly-Fadiel, Alicia, Benitez, Javier, Bernardini, Marcus Q., Bjorge, Line, Black, Amanda, Bogdanova, Natalia V., Bolton, Kelly L., Brenton, James D., Budzilowska, Agnieszka, Butzow, Ralf, Cai, Hui, Campbell, Ian, Cannioto, Rikki, Chang-Claude, Jenny, Chanock, Stephen J., Chen, Kexin, Chenevix-Trench, Georgia, Chiew, Yoke-Eng, Cook, Linda S., DeFazio, Anna, Dennis, Joe, Doherty, Jennifer A., Dörk, Thilo, du Bois, Andreas, Dürst, Matthias, Eccles, Diana M., Ene, Gabrielle, Fasching, Peter A., Flanagan, James M., Fortner, Renée T., Fostira, Florentia, Gentry-Maharaj, Aleksandra, Giles, Graham G., Goodman, Marc T., Gronwald, Jacek, Haiman, Christopher A., Håkansson, Niclas, Heitz, Florian, Hildebrandt, Michelle A.T., Høgdall, Estrid, Høgdall, Claus K., Huang, Ruea-Yea, Jensen, Allan, Jones, Michael E., Kang, Daehee, Karlan, Beth Y., Karnezis, Anthony N., Kelemen, Linda E., Kennedy, Catherine J., Khusnutdinova, Elza K., Kiemeney, Lambertus A., Kjaer, Susanne K., Kupryjanczyk, Jolanta, Labrie, Marilyne, Lambrechts, Diether, Larson, Melissa C., Le, Nhu D., Lester, Jenny, Li, Lian, Lubiński, Jan, Lush, Michael, Marks, Jeffrey R., Matsuo, Keitaro, May, Taymaa, McLaughlin, John R., McNeish, Iain A., Menon, Usha, Missmer, Stacey, Modugno, Francesmary, Moffitt, Melissa, Monteiro, Alvaro N., Moysich, Kirsten B., Narod, Steven A., Nguyen-Dumont, Tu, Odunsi, Kunle, Olsson, Håkan, Onland-Moret, N. Charlotte, Park, Sue K., Pejovic, Tanja, Permuth, Jennifer B., Piskorz, Anna, Prokofyeva, Darya, Riggan, Marjorie J., Risch, Harvey A., Rodríguez-Antona, Cristina, Rossing, Mary Anne, Sandler, Dale P., Setiawan, V. Wendy, Shan, Kang, Song, Honglin, Southey, Melissa C., Steed, Helen, Sutphen, Rebecca, Swerdlow, Anthony J., Teo, Soo Hwang, Terry, Kathryn L., Thompson, Pamela J., Vestrheim Thomsen, Liv Cecilie, Titus, Linda, Trabert, Britton, Travis, Ruth, Tworoger, Shelley S., Valen, Ellen, Van Nieuwenhuysen, Els, Edwards, Digna Velez, Vierkant, Robert A., Webb, Penelope M., Weinberg, Clarice R., Weise, Rayna Matsuno, Wentzensen, Nicolas, White, Emily, Winham, Stacey J., Wolk, Alicja, Woo, Yin-Ling, Wu, Anna H., Yan, Li, Yannoukakos, Drakoulis, Zeinomar, Nur, Zheng, Wei, Ziogas, Argyrios, Berchuck, Andrew, Goode, Ellen L., Huntsman, David G., Pearce, Celeste L., Ramus, Susan J., Sellers, Thomas A., Freedman, Matthew L., Lawrenson, Kate, Schildkraut, Joellen M., Hazelett, Dennis, Plummer, Jasmine T., Kar, Siddhartha, Jones, Michelle R., Pharoah, Paul D.P., and Gayther, Simon A.

Published
2024
Full Text
View/download PDF

5. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Author

Abadie-Lacourtoisie, Sophie, Andreetta, Claudia, Anzizar, Nerea, Aoki, Daiseuke, Barretina-Ginesta, Maria-Pilar, Battista, Marco, Bellier, Charlotte, Bentzen, Anne Gry, Berton, Dominique, Billemont, Bertrand, Bjørge, Line, Bjurberg, Maria, Black, Destin, Bologna, Alessandra, Braicu, Elena Ioana, Casanova, Claudia, Chekerov, Radoslav, Chevalier, Annick, Cueva, Juan Fernando, Czogalla, Bastian, Delanoy, Nicolas, Denschlag, Dominik, Derke, Oscar, Eichbaum, Michael, Enomoto, Takayuki, Esteban, Carmen, Fabbro, Michel, Fehm, Tanja, Ferrero, Annamaria, Fleisch, Markus, Floquet, Anne, Frassoldati, Antonio, Gaba, Lydia, Gadducci, Angiolo, García, Yolanda, Geuna, Elena, Guerra, Eva, Hanker, Lars, Hardy-Bessard, Anne-Claire, Harter, Philipp, Hasegawa, Kosei, Hellman, Kristina, Herrero, Ana, Hilpert, Felix, Katsaros, Dionyssios, Koegel, Matthias, Koliadi, Anthoula, Kurtz, Jean-Emmanuel, Lampe, Bjoern, Lissoni, Andrea Alberto, Lortholary, Alain, Mangili, Giorgia, Mansi, Laura, Marmé, Frederik, Mathews, Cara, Mina, William, Minobe, Shinichiro, Moxley, Katherine, Nagao, Shoji, Nicoletto, Ornella, Nishino, Koji, Nishio, Hiroshi, Nishio, Shin, Oaknin, Ana, Onstad, Michaela, Pardo, Beatriz, Pérez-Fidalgo, J Alejandro, Pisano, Carmela, Poveda, Andrés, Radosa, Julia, Randall, Leslie M., Ray-Coquard, Isabelle, Redondo, Andrés, Richardson, Debra, Romero, Ignacio, Ronzino, Graziana, Rubio, Maria Jesús, Selle, Frederic, Takekuma, Munetaka, Takeshima, Nobuhiro, Tasca, Giulia, Tewari, Krishnansu, Todo, Yukiharu, Valabrega, Giorgio, Wimberger, Pauline, Woelber, Linn, Yamaguchi, Satoshi, You, Benoît, Yunokawa, Mayu, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, De Giorgi, Ugo, Lindemann, Kristina, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Angelergues, Antoine, Fariñas-Madrid, Lorena, Lorusso, Domenica, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Lebreton, Coriolan, Dahlstrand, Hanna, D'Hondt, Véronique, and Randall, Leslie M

Published
2024
Full Text
View/download PDF

7. IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results

Author

Puco, Katarina, primary, Fagereng, Gro Live, additional, Brabrand, Sigmund, additional, Niehusmann, Pitt, additional, Støre Blix, Egil, additional, Samdal Steinskog, Eli Sihn, additional, Haug, Åse, additional, Fredvik Torkildsen, Cecilie, additional, Oppedal, Irja Alida, additional, Meltzer, Sebastian, additional, Flobak, Åsmund, additional, Johansson, Kajsa Anna Margareta, additional, Bjørge, Line, additional, Hjortland, Geir Olav, additional, Dalhaug, Astrid, additional, Lund, Jo-Åsmund, additional, Gilje, Bjørnar, additional, Grønlie Cameron, Marte, additional, Hovland, Randi, additional, Falk, Ragnhild S., additional, Smeland, Sigbjørn, additional, Giercksky Russnes, Hege Elisabeth, additional, Taskén, Kjetil, additional, and Helland, Åslaug, additional

Published
2024
Full Text
View/download PDF

8. Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk

Author

Yang, Yaohua, Wu, Lang, Shu, Xiang, Lu, Yingchang, Shu, Xiao-Ou, Cai, Qiuyin, Beeghly-Fadiel, Alicia, Li, Bingshan, Ye, Fei, Berchuck, Andrew, Anton-Culver, Hoda, Banerjee, Susana, Benitez, Javier, Bjørge, Line, Brenton, James D, Butzow, Ralf, Campbell, Ian G, Chang-Claude, Jenny, Chen, Kexin, Cook, Linda S, Cramer, Daniel W, deFazio, Anna, Dennis, Joe, Doherty, Jennifer A, Dörk, Thilo, Eccles, Diana M, Edwards, Digna Velez, Fasching, Peter A, Fortner, Renée T, Gayther, Simon A, Giles, Graham G, Glasspool, Rosalind M, Goode, Ellen L, Goodman, Marc T, Gronwald, Jacek, Harris, Holly R, Heitz, Florian, Hildebrandt, Michelle A, Høgdall, Estrid, Høgdall, Claus K, Huntsman, David G, Kar, Siddhartha P, Karlan, Beth Y, Kelemen, Linda E, Kiemeney, Lambertus A, Kjaer, Susanne K, Koushik, Anita, Lambrechts, Diether, Le, Nhu D, Levine, Douglas A, Massuger, Leon F, Matsuo, Keitaro, May, Taymaa, McNeish, Iain A, Menon, Usha, Modugno, Francesmary, Monteiro, Alvaro N, Moorman, Patricia G, Moysich, Kirsten B, Ness, Roberta B, Nevanlinna, Heli, Olsson, Håkan, Onland-Moret, N Charlotte, Park, Sue K, Paul, James, Pearce, Celeste L, Pejovic, Tanja, Phelan, Catherine M, Pike, Malcolm C, Ramus, Susan J, Riboli, Elio, Rodriguez-Antona, Cristina, Romieu, Isabelle, Sandler, Dale P, Schildkraut, Joellen M, Setiawan, Veronica W, Shan, Kang, Siddiqui, Nadeem, Sieh, Weiva, Stampfer, Meir J, Sutphen, Rebecca, Swerdlow, Anthony J, Szafron, Lukasz M, Teo, Soo Hwang, Tworoger, Shelley S, Tyrer, Jonathan P, Webb, Penelope M, Wentzensen, Nicolas, White, Emily, Willett, Walter C, Wolk, Alicja, Woo, Yin Ling, Wu, Anna H, Yan, Li, Yannoukakos, Drakoulis, Chenevix-Trench, Georgia, Sellers, Thomas A, Pharoah, Paul DP, Zheng, Wei, and Long, Jirong

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Genetics, Biotechnology, Rare Diseases, Ovarian Cancer, Cancer Genomics, Prevention, Women's Health, Cancer, Clinical Research, Human Genome, 2.1 Biological and endogenous factors, Biomarkers, Tumor, Carcinoma, Ovarian Epithelial, Cohort Studies, DNA Methylation, Female, Genetic Predisposition to Disease, Humans, Models, Genetic, Ovarian Neoplasms, Predictive Value of Tests, Risk, White People, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

DNA methylation is instrumental for gene regulation. Global changes in the epigenetic landscape have been recognized as a hallmark of cancer. However, the role of DNA methylation in epithelial ovarian cancer (EOC) remains unclear. In this study, high-density genetic and DNA methylation data in white blood cells from the Framingham Heart Study (N = 1,595) were used to build genetic models to predict DNA methylation levels. These prediction models were then applied to the summary statistics of a genome-wide association study (GWAS) of ovarian cancer including 22,406 EOC cases and 40,941 controls to investigate genetically predicted DNA methylation levels in association with EOC risk. Among 62,938 CpG sites investigated, genetically predicted methylation levels at 89 CpG were significantly associated with EOC risk at a Bonferroni-corrected threshold of P < 7.94 × 10-7. Of them, 87 were located at GWAS-identified EOC susceptibility regions and two resided in a genomic region not previously reported to be associated with EOC risk. Integrative analyses of genetic, methylation, and gene expression data identified consistent directions of associations across 12 CpG, five genes, and EOC risk, suggesting that methylation at these 12 CpG may influence EOC risk by regulating expression of these five genes, namely MAPT, HOXB3, ABHD8, ARHGAP27, and SKAP1. We identified novel DNA methylation markers associated with EOC risk and propose that methylation at multiple CpG may affect EOC risk via regulation of gene expression. SIGNIFICANCE: Identification of novel DNA methylation markers associated with EOC risk suggests that methylation at multiple CpG may affect EOC risk through regulation of gene expression.

Published
2019

9. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

Author

Mahner, Sven, Reuss, Alexander, du Bois, Andreas, Grimm, Christoph, Marth, Christian, Berger, Regina, Concin, Nicole, Chang, Ting-Chang, Ochiai, Kazunori, Gebski, Val, Davis, Alison, Beale, Philip, Vergote, Ignace, Kridelka, Frédéric, Denys, Hannelore, Vandecaveye, Vincent, Candido dos Reis, Francisco Jose, Del Pilar Estevez Diz, Maria, Stuart, Gavin, MacKay, Helen, Carey, Mark, Cibula, David, Dundr (path), Pavel, Dorigo, Oliver, Berek, Jonathan, O'Donnell, Dearbhaile, Saadeh, Abu, Boere, Ingrid, Lok, Christianne, Coronado, Pluvio, Ottevanger, Nelleke, Tan, David SP, Ng, Joseph, Gonzalez Martin, Antonio, Oaknin, Ana, Poveda, Andres, Perez Fidalgo, Alejandro, Rauh-Hain, Alejandro, Lu, Karen, López-Zavala, Carlos, Gómez-García, Eva María, Ray-Coquard, Isabelle, Paoletti, Xavier, Kurtz, Jean-Emmanuel, Joly, Florence, Votan, Bénédicte, Bookman, Michael, Moore, Kathleen, Arend, Rebecca, Fujiwara, Keiichi, Fujiwara, Hiroyuki, Hasegawa, Kosei, Bruchim, Ilan, Tsoref, Dalia, Oda, Katsutoshi, Okamoto, Aikou, Enomoto, Takayuki, Michel, Dayana, Kim, Hee-Seung, Lee, Jung-Yun, Mukhopadhyay, Asima, Katsaros, Dionyssios, Colombo, Nicoletta, Pignata, Sandro, Lorusso, Domenica, Scambia, Giovanni, Kohn, Elise, Lee, Jung-Min, McNeish, Iain, Nicum, Shibani, Farrelly, Laura, Sehouli, Jalid, Keller, Maren, Braicu, Elena, Bjørge, Line, Mirza, Mansoor Raza, Auranen, Annika, Welch, Stephen, Oza, Amit M, Heinzelmann, Viola, Gourley, Charlie, Roxburgh, Patricia, Herrington, C Simon, Glasspool, Ros, Zang, Rongyu, Zhu, Jianqing, Gonzalez-Martin, Antonio, Kohn, Elise C, Berek, Jonathan S, Tan, David S P, Stuart, Gavin C E, and Bookman, Michael A

Published
2022
Full Text
View/download PDF

11. Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway

Author

Helland, Åslaug, Russnes, Hege G., Fagereng, Gro Live, Al-Shibli, Khalid, Andersson, Yvonne, Berg, Thomas, Bjørge, Line, Blix, Egil, Bjerkehagen, Bodil, Brabrand, Sigmund, Cameron, Marte Grønlie, Dalhaug, Astrid, Dietzel, Dalia, Dønnem, Tom, Enerly, Espen, Flobak, Åsmund, Fluge, Sverre, Gilje, Bjørnar, Gjertsen, Bjørn Tore, Grønberg, Bjørn Henning, Grønås, Kari, Guren, Tormod, Hamre, Hanne, Haug, Åse, Heinrich, Daniel, Hjortland, Geir Olav, Hovig, Eivind, Hovland, Randi, Iversen, Ann-Charlotte, Janssen, Emiel, Kyte, Jon Amund, von der Lippe Gythfeldt, Hedda, Lothe, Ragnhild, Lund, Jo-Åsmund, Meza-Zepeda, Leonardo, Munthe-Kaas, Monica Cheng, Nguyen, Olav Toai Duc, Niehusmann, Pitt, Nilsen, Hilde, Puco, Katarina, Ree, Anne Hansen, Riste, Tonje Bøyum, Semb, Karin, Steinskog, Eli Sihn Samdal, Stensvold, Andreas, Suhrke, Pål, Tennøe, Øyvind, Tjønnfjord, Geir E., Vassbotn, Liv Jorunn, Aas, Eline, Aasebø, Kristine, Tasken, Kjetil, and Smeland, Sigbjørn

Published
2022
Full Text
View/download PDF

13. Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway

Author

Helland, Åslaug, Russnes, Hege G., Fagereng, Gro Live, Al-Shibli, Khalid, Andersson, Yvonne, Berg, Thomas, Bjørge, Line, Blix, Egil, Bjerkehagen, Bodil, Brabrand, Sigmund, Cameron, Marte Grønlie, Dalhaug, Astrid, Dietzel, Dalia, Dønnem, Tom, Enerly, Espen, Flobak, Åsmund, Fluge, Sverre, Gilje, Bjørnar, Gjertsen, Bjørn Tore, Grønberg, Bjørn Henning, Grønås, Kari, Guren, Tormod, Hamre, Hanne, Haug, Åse, Heinrich, Daniel, Hjortland, Geir Olav, Hovig, Eivind, Hovland, Randi, Iversen, Ann-Charlotte, Janssen, Emiel, Kyte, Jon Amund, von der Lippe Gythfeldt, Hedda, Lothe, Ragnhild, Lund, Jo-Åsmund, Meza-Zepeda, Leonardo, Munthe-Kaas, Monica Cheng, Nguyen, Olav Toai Duc, Niehusmann, Pitt, Nilsen, Hilde, Puco, Katarina, Ree, Anne Hansen, Riste, Tonje Bøyum, Semb, Karin, Steinskog, Eli Sihn Samdal, Stensvold, Andreas, Suhrke, Pål, Tennøe, Øyvind, Tjønnfjord, Geir E., Vassbotn, Liv Jorunn, Aas, Eline, Aasebø, Kristine, Tasken, Kjetil, and Smeland, Sigbjørn

Published
2022
Full Text
View/download PDF

15. The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples

Author

Barrett, James E., Herzog, Chiara, Jones, Allison, Leavy, Olivia C., Evans, Iona, Knapp, Susanne, Reisel, Daniel, Nazarenko, Tatiana, Kim, Yoo-Na, Franchi, Dorella, Ryan, Andy, Franks, Joanna, Bjørge, Line, Zikan, Michal, Cibula, David, Harbeck, Nadia, Colombo, Nicoletta, Dudbridge, Frank, Jones, Louise, Sundström, Karin, Dillner, Joakim, Rådestad, Angelique Flöter, Gemzell-Danielsson, Kristina, Pashayan, Nora, and Widschwendter, Martin

Published
2022
Full Text
View/download PDF

16. A national precision cancer medicine implementation initiative for Norway

Author

Taskén, Kjetil, Russnes, Hege E. G., Aas, Eline, Bjørge, Line, Blix, Egil S., Enerly, Espen, Fagereng, Gro L., Flobak, Åsmund, Gilje, Bjørnar, Gjertsen, Bjørn T., Guren, Tormod K., Heix, Jutta, Hovig, Eivind, Hovland, Randi, Lønning, Per E., Meza-Zepeda, Leonardo A., Mæhle, Per M., Nilsen, Hilde L., Thoresen, Steinar Ø., Widerberg, Ketil, Smeland, Sigbjørn, and Helland, Åslaug

Published
2022
Full Text
View/download PDF

17. Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16

Author

Casey, Nicholas P, primary, Kleinmanns, Katrin, additional, Forcados, Christopher, additional, Gelebart, Pascal F, additional, Joaquina, Sandy, additional, Lode, Martine, additional, Benard, Emmanuelle, additional, Kaveh, Fatemeh, additional, Caulier, Benjamin, additional, Helgestad Gjerde, Christiane, additional, García de Jalón, Elvira, additional, Warren, David J, additional, Lindemann, Kristina, additional, Rokkones, Erik, additional, Davidson, Ben, additional, Myhre, Marit Renee, additional, Kvalheim, Gunnar, additional, Bjørge, Line, additional, McCormack, Emmet, additional, Inderberg, Else Marit, additional, and Wälchli, Sébastien, additional

Published
2024
Full Text
View/download PDF

19. Secondary Cytoreductive Surgery in Relapsed Platinum-Sensitive Epithelial Ovarian Cancer: A Systematic Review of Randomized Controlled Trials.

Author

Myhr, Andrea Svennevik, Bjørge, Line, and Torkildsen, Cecilie Fredvik

Subjects
*PLATINUM compounds, *CANCER relapse, *RESEARCH funding, *OVARIAN tumors, *CYTOREDUCTIVE surgery, *TREATMENT effectiveness, *CANCER chemotherapy, *QUALITY of life, *PROGRESSION-free survival, *OVERALL survival
Abstract

Simple Summary: Secondary cytoreductive surgery is a treatment option for patients with relapsed platinum-sensitive epithelial ovarian cancer, yet the precise indications and criteria for patient selection remain to be outlined. Furthermore, the impact on progression-free and overall survival remains unclear. The objective of this systematic review was to determine the precise indications for secondary cytoreductive surgery and to elucidate the factors contributing to favorable outcomes associated with the intervention compared to conventional treatment modalities like standard-of-care chemotherapy. Our review confirmed that secondary cytoreductive surgery maintains morbidity, mortality, and quality of life standards for patients. While the trials included utilized different selection criteria for the procedure, our findings underscore the importance of careful patient selection to improve survival in conjunction with conventional chemotherapy. Secondary cytoreductive surgery is a treatment option for relapsed platinum-sensitive epithelial ovarian cancer, but no clear indications are defined for the procedure. This systematic review aims to establish clear indications and compare outcomes versus standard-of-care chemotherapy. We conducted an electronic literature search across three databases and identified 2033 articles, including three phase 3 randomized controlled trials (RCT). The review adhered to PRISMA 2020 guidelines and was registered in PROSPERO (no. CRD42022379817). Despite varying patient selection methods, surgery plus chemotherapy demonstrated significantly prolonged progression-free survival compared to chemotherapy alone. However, overall survival outcomes were inconsistent: while GOG-0213 did not show extended overall survival, recent studies with stricter defined criteria for surgery (SOC-1 and DESKTOP-III) reported improved overall survival with the addition of surgery. Morbidity and mortality rates were low, with no difference in quality of life between the surgery and no-surgery groups. In conclusion, cytoreductive surgery presents a promising option for recurrent epithelial ovarian cancer treatment. Nonetheless, well-defined selection criteria appear crucial for achieving increased overall survival compared to conventional treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients.

Author

Torkildsen, Cecilie Fredvik, Austdal, Marie, Jarmund, Anders Hagen, Kleinmanns, Katrin, Lamark, Eva Karin, Nilsen, Elisabeth Berge, Stefansson, Ingunn, Sande, Ragnar Kvie, Iversen, Ann-Charlotte, Thomsen, Liv Cecilie Vestrheim, and Bjørge, Line

Subjects
PHENOTYPES, CYTOREDUCTIVE surgery, THERAPEUTICS, IMMUNITY, OVERALL survival, GLEASON grading system
Abstract

Despite advances in surgical and therapeutic approaches, high-grade serous ovarian carcinoma (HGSOC) prognosis remains poor. Surgery is an indispensable component of therapeutic protocols, as removal of all visible tumor lesions (cytoreduction) profoundly improves the overall survival. Enhanced predictive tools for assessing cytoreduction are essential to optimize therapeutic precision. Patients' immune status broadly reflects the tumor cell biological behavior and the patient responses to disease and treatment. Serum cytokine profiling is a sensitive measure of immune adaption and deviation, yet its integration into treatment paradigms is underexplored. This study is part of the IMPACT trial (NCT03378297) and aimed to characterize immune responses before and during primary treatment for HGSOC to identify biomarkers for treatment selection and prognosis. Longitudinal serum samples from 22 patients were collected from diagnosis until response evaluation. Patients underwent primary cytoreductive surgery or neoadjuvant chemotherapy (NACT) based on laparoscopy scoring. Twenty-seven serum cytokines analyzed by Bio-Plex 200, revealed two immune phenotypes at diagnosis: Immune High with marked higher serum cytokine levels than Immune Low. The immune phenotypes reflected the laparoscopy scoring and allocation to surgical treatment. The five Immune High patients undergoing primary cytoreductive surgery exhibited immune mobilization and extended progression-free survival, compared to the Immune Low patients undergoing the same treatment. Both laparoscopy and cytoreductive surgery induced substantial and transient changes in serum cytokines, with upregulation of the inflammatory cytokine IL-6 and downregulation of the multifunctional cytokines IP-10, Eotaxin, IL-4, and IL-7. Over the study period, cytokine levels uniformly decreased in all patients, leading to the elimination of the initial immune phenotypes regardless of treatment choice. This study reveals distinct pre-treatment immune phenotypes in HGSOC patients that might be informative for treatment stratification and prognosis. This potential novel biomarker holds promise as a foundation for improved assessment of treatment responses in patients with HGSOC. ClinicalTrials.gov Identifier: NCT03378297. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Real-world data on niraparib maintenance treatment in patients with non-gBRCA mutated platinum-sensitive recurrent ovarian cancer

Author

Vilming, Bente, primary, Fallås Dahl, Jørgen, additional, Bentzen, Anne Gry, additional, Ingebrigtsen, Vibeke Anett, additional, Berge Nilsen, Elisabeth, additional, Vistad, Ingvild, additional, Dørum, Anne, additional, Solheim, Olesya, additional, Bjørge, Line, additional, Zucknick, Manuela, additional, Aune, Guro, additional, and Lindemann, Kristina, additional

Published
2023
Full Text
View/download PDF

26. Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk.

Author

Kar, Siddhartha P, Tyrer, Jonathan P, Li, Qiyuan, Lawrenson, Kate, Aben, Katja KH, Anton-Culver, Hoda, Antonenkova, Natalia, Chenevix-Trench, Georgia, Australian Cancer Study, Australian Ovarian Cancer Study Group, Baker, Helen, Bandera, Elisa V, Bean, Yukie T, Beckmann, Matthias W, Berchuck, Andrew, Bisogna, Maria, Bjørge, Line, Bogdanova, Natalia, Brinton, Louise, Brooks-Wilson, Angela, Butzow, Ralf, Campbell, Ian, Carty, Karen, Chang-Claude, Jenny, Chen, Yian Ann, Chen, Zhihua, Cook, Linda S, Cramer, Daniel, Cunningham, Julie M, Cybulski, Cezary, Dansonka-Mieszkowska, Agnieszka, Dennis, Joe, Dicks, Ed, Doherty, Jennifer A, Dörk, Thilo, du Bois, Andreas, Dürst, Matthias, Eccles, Diana, Easton, Douglas F, Edwards, Robert P, Ekici, Arif B, Fasching, Peter A, Fridley, Brooke L, Gao, Yu-Tang, Gentry-Maharaj, Aleksandra, Giles, Graham G, Glasspool, Rosalind, Goode, Ellen L, Goodman, Marc T, Grownwald, Jacek, Harrington, Patricia, Harter, Philipp, Hein, Alexander, Heitz, Florian, Hildebrandt, Michelle AT, Hillemanns, Peter, Hogdall, Estrid, Hogdall, Claus K, Hosono, Satoyo, Iversen, Edwin S, Jakubowska, Anna, Paul, James, Jensen, Allan, Ji, Bu-Tian, Karlan, Beth Y, Kjaer, Susanne K, Kelemen, Linda E, Kellar, Melissa, Kelley, Joseph, Kiemeney, Lambertus A, Krakstad, Camilla, Kupryjanczyk, Jolanta, Lambrechts, Diether, Lambrechts, Sandrina, Le, Nhu D, Lee, Alice W, Lele, Shashi, Leminen, Arto, Lester, Jenny, Levine, Douglas A, Liang, Dong, Lissowska, Jolanta, Lu, Karen, Lubinski, Jan, Lundvall, Lene, Massuger, Leon, Matsuo, Keitaro, McGuire, Valerie, McLaughlin, John R, McNeish, Iain A, Menon, Usha, Modugno, Francesmary, Moysich, Kirsten B, Narod, Steven A, Nedergaard, Lotte, Ness, Roberta B, Nevanlinna, Heli, Odunsi, Kunle, Olson, Sara H, and Orlow, Irene

Subjects
Australian Cancer Study, Australian Ovarian Cancer Study Group, Humans, Cystadenocarcinoma, Serous, Ovarian Neoplasms, Genetic Predisposition to Disease, Nuclear Proteins, Transcription Factors, DNA, Neoplasm, Morbidity, Risk Factors, Gene Expression Regulation, Neoplastic, Genotype, Female, Genome-Wide Association Study, Global Health, Ovarian Cancer, Biotechnology, Cancer, Genetics, Rare Diseases, Prevention, Human Genome, 2.1 Biological and endogenous factors, Epidemiology, Medical and Health Sciences
Abstract

BackgroundGenome-wide association studies (GWAS) have so far reported 12 loci associated with serous epithelial ovarian cancer (EOC) risk. We hypothesized that some of these loci function through nearby transcription factor (TF) genes and that putative target genes of these TFs as identified by coexpression may also be enriched for additional EOC risk associations.MethodsWe selected TF genes within 1 Mb of the top signal at the 12 genome-wide significant risk loci. Mutual information, a form of correlation, was used to build networks of genes strongly coexpressed with each selected TF gene in the unified microarray dataset of 489 serous EOC tumors from The Cancer Genome Atlas. Genes represented in this dataset were subsequently ranked using a gene-level test based on results for germline SNPs from a serous EOC GWAS meta-analysis (2,196 cases/4,396 controls).ResultsGene set enrichment analysis identified six networks centered on TF genes (HOXB2, HOXB5, HOXB6, HOXB7 at 17q21.32 and HOXD1, HOXD3 at 2q31) that were significantly enriched for genes from the risk-associated end of the ranked list (P < 0.05 and FDR < 0.05). These results were replicated (P < 0.05) using an independent association study (7,035 cases/21,693 controls). Genes underlying enrichment in the six networks were pooled into a combined network.ConclusionWe identified a HOX-centric network associated with serous EOC risk containing several genes with known or emerging roles in serous EOC development.ImpactNetwork analysis integrating large, context-specific datasets has the potential to offer mechanistic insights into cancer susceptibility and prioritize genes for experimental characterization.

Published
2015

27. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

Author

Mirza, Mansoor Raza, Åvall Lundqvist, Elisabeth, Birrer, Michael J, dePont Christensen, Rene, Nyvang, Gitte-Bettina, Malander, Susanne, Anttila, Maarit, Werner, Theresa L, Lund, Bente, Lindahl, Gabriel, Hietanen, Sakari, Peen, Ulla, Dimoula, Maria, Roed, Henrik, Ør Knudsen, Anja, Staff, Synnöve, Krog Vistisen, Anders, Bjørge, Line, and Mäenpää, Johanna U

Published
2019
Full Text
View/download PDF

30. Combining Mass Cytometry Data by CyTOFmerge Reveals Additional Cell Phenotypes in the Heterogeneous Ovarian Cancer Tumor Microenvironment: A Pilot Study

Author

Thomsen, Liv Cecilie Vestrheim, primary, Kleinmanns, Katrin, additional, Anandan, Shamundeeswari, additional, Gullaksen, Stein-Erik, additional, Abdelaal, Tamim, additional, Iversen, Grete Alrek, additional, Akslen, Lars Andreas, additional, McCormack, Emmet, additional, and Bjørge, Line, additional

Published
2023
Full Text
View/download PDF

31. TP53 mutation and human papilloma virus status as independent prognostic factors in a Norwegian cohort of vulva squamous cell carcinoma

Author

Dongre, Harsh Nitin, primary, Elnour, Rammah, additional, Tornaas, Stian, additional, Fromreide, Siren, additional, Thomsen, Liv Cecilie Vestrheim, additional, Kolseth, Ingrid Benedicte Moss, additional, Nginamau, Elisabeth Sivy, additional, Johannessen, Anne Christine, additional, Vintermyr, Olav Karsten, additional, Costea, Daniela Elena, additional, and Bjørge, Line, additional

Published
2023
Full Text
View/download PDF

33. #219 Determinants of treatment decision-making regarding maintenance therapy in advanced epithelial ovarian cancer: a European delphi study to find consensus

Author

You, Benoit, primary, Pérez-Fidalgo, Alejandro, additional, Schmalfeldt, Barbara, additional, George, Angela, additional, Gourley, Charlie, additional, Pignata, Sandro, additional, Lorusso, Domenica, additional, Barretina-Ginesta, Maria-Pilar, additional, Romero, Ignacio, additional, Grimm, Christoph, additional, Gorp, Toon Van, additional, Rossing, Maria, additional, Collins, Dearbhaile, additional, Fernebro, Josefin, additional, Bjørge, Line, additional, Leary, Alexandra, additional, Rouge, Thibault De La Motte, additional, Harter, Philipp, additional, Kurzeder, Christian, additional, and Savva-Bordalo, Joana, additional

Published
2023
Full Text
View/download PDF

34. Dyslipidemia and immunological deviation in diagnosed preeclampsia

Author

Jarmund, Anders Hagen, primary, Rossevatn Svoren, Åse Turid, additional, Buer, Signe, additional, Ryssdal, Mariell, additional, Steinkjer, Bjørg, additional, Bjørge, Line, additional, Vestrheim Thomsen, Liv Cecilie, additional, Vanky, Eszter, additional, Giskeødegård, Guro F., additional, and Iversen, Ann-Charlotte, additional

Published
2023
Full Text
View/download PDF

35. #267 Quality-adjusted time without symptoms of disease or toxicity in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel in the ENGOT-EN6/GOG-3031/RUBY trial

Author

Chase, Dana, primary, Bjørge, Line, additional, Coleman, Robert L, additional, Zub, Oleksandr, additional, Miller, Eirwen, additional, Angioli, Roberto, additional, Mathews, Cara, additional, Hanker, Lars C, additional, Teneriello, Michael G, additional, Reyners, Anna, additional, Powell, Matthew, additional, Gilbert, Lucy, additional, Cloven, Noelle, additional, Gill, Sarah, additional, Monk, Bradley J, additional, Pothuri, Bhavana, additional, Garside, Jamie, additional, Allonby, Odette, additional, Mccourt, Carolyn, additional, and Mirza, Mansoor Raza, additional

Published
2023
Full Text
View/download PDF

39. TP53 mutation and human papilloma virus status as independent prognostic factors in a Norwegian cohort of vulva squamous cell carcinoma.

Author

Dongre, Harsh Nitin, Elnour, Rammah, Tornaas, Stian, Fromreide, Siren, Thomsen, Liv Cecilie Vestrheim, Kolseth, Ingrid Benedicte Moss, Nginamau, Elisabeth Sivy, Johannessen, Anne Christine, Vintermyr, Olav Karsten, Costea, Daniela Elena, and Bjørge, Line

Subjects
HUMAN papillomavirus, SQUAMOUS cell carcinoma, PROGNOSIS, BRAF genes, VULVA, PROGRESSION-free survival
Abstract

Introduction: Vulva squamous cell carcinoma (VSCC) develops through two separate molecular pathways—one involving high‐risk human papilloma virus infection (HPV‐associated), and the other without HPV infection (HPV‐independent) often involving TP53 mutation. HPV‐associated VSCC generally has a better progression‐free survival than HPV‐independent VSCC. The aim of this study was to determine TP53 mutation status using immunohistochemistry, compare different methods of HPV detection and correlate both with survival in a retrospective cohort of 123 patients with VSCC. Material and methods: Immunohistochemistry for p53, Ki67 and p16INK4A (a surrogate marker for HPV infection) was performed on formalin‐fixed paraffin‐embedded tissues from a cohort of surgically treated VSCC patients to identify molecular subtypes of VSCC. Presence of HPV infection was detected by HPV DNA PCR and HPV mRNA in situ hybridization (ISH). The Pearson chi‐square test and multivariable Cox regression model were used to investigate the association of different parameters with progression‐free survival and disease‐specific survival (DSS), and Kaplan–Meier curves were used to show the association of different parameters with survival. Results: The results of p53 and p16INK4A immunohistochemistry confirmed three VSCC subtypes associated with different prognosis. The TP53 mutation status was identified as an independent prognostic factor of worse progression‐free survival (p = 0.024) after adjustment for FIGO stage. p16INK4A immunohistochemistry, mRNA ISH, and DNA PCR had excellent concordance in terms of HPV detection. According to the multivariable Cox regression model, the presence of hrHPV mRNA correlated significantly with increased progression‐free survival (p = 0.040) and DSS (p = 0.045), after adjustment for other confounders. Conclusions: p53 and p16INK4A immunohistochemistry stratify VSCC cohort into three subtypes with TP53mutated patients having the worst prognosis. The detection of hrHPV mRNA by ISH was an independent predictor of increased survival. Thus, the combined detection of p53 and HPV mRNA might improve risk stratification in VSCC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Supplementary information from Changes in Chromatin Structure in Curettage Specimens Identifies High-Risk Patients in Endometrial Cancer

Author

Hveem, Tarjei S., primary, Njølstad, Tormund S., primary, Nielsen, Birgitte, primary, Syvertsen, Rolf Anders, primary, Nesheim, John Arne, primary, Kjæreng, Marna L., primary, Kildal, Wanja, primary, Pradhan, Manohar, primary, Marcickiewicz, Janusz, primary, Tingulstad, Solveig, primary, Staff, Anne C., primary, Haugland, Hans K., primary, Eraker, Runar, primary, Oddenes, Klaus, primary, Rokne, Jan A., primary, Tjugum, Jostein, primary, Lode, Margaret S., primary, Amant, Frederic, primary, Werner, Henrica M.J., primary, Bjørge, Line, primary, Albregtsen, Fritz, primary, Liestøl, Knut, primary, Salvesen, Helga B., primary, Trovik, Jone, primary, and Danielsen, Håvard E., primary

Published
2023
Full Text
View/download PDF

42. Data from Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk

Author

Kar, Siddhartha P., primary, Tyrer, Jonathan P., primary, Li, Qiyuan, primary, Lawrenson, Kate, primary, Aben, Katja K.H., primary, Anton-Culver, Hoda, primary, Antonenkova, Natalia, primary, Chenevix-Trench, Georgia, primary, Baker, Helen, primary, Bandera, Elisa V., primary, Bean, Yukie T., primary, Beckmann, Matthias W., primary, Berchuck, Andrew, primary, Bisogna, Maria, primary, Bjørge, Line, primary, Bogdanova, Natalia, primary, Brinton, Louise, primary, Brooks-Wilson, Angela, primary, Butzow, Ralf, primary, Campbell, Ian, primary, Carty, Karen, primary, Chang-Claude, Jenny, primary, Chen, Yian Ann, primary, Chen, Zhihua, primary, Cook, Linda S., primary, Cramer, Daniel, primary, Cunningham, Julie M., primary, Cybulski, Cezary, primary, Dansonka-Mieszkowska, Agnieszka, primary, Dennis, Joe, primary, Dicks, Ed, primary, Doherty, Jennifer A., primary, Dörk, Thilo, primary, du Bois, Andreas, primary, Dürst, Matthias, primary, Eccles, Diana, primary, Easton, Douglas F., primary, Edwards, Robert P., primary, Ekici, Arif B., primary, Fasching, Peter A., primary, Fridley, Brooke L., primary, Gao, Yu-Tang, primary, Gentry-Maharaj, Aleksandra, primary, Giles, Graham G., primary, Glasspool, Rosalind, primary, Goode, Ellen L., primary, Goodman, Marc T., primary, Grownwald, Jacek, primary, Harrington, Patricia, primary, Harter, Philipp, primary, Hein, Alexander, primary, Heitz, Florian, primary, Hildebrandt, Michelle A.T., primary, Hillemanns, Peter, primary, Hogdall, Estrid, primary, Hogdall, Claus K., primary, Hosono, Satoyo, primary, Iversen, Edwin S., primary, Jakubowska, Anna, primary, Paul, James, primary, Jensen, Allan, primary, Ji, Bu-Tian, primary, Karlan, Beth Y., primary, Kjaer, Susanne K., primary, Kelemen, Linda E., primary, Kellar, Melissa, primary, Kelley, Joseph, primary, Kiemeney, Lambertus A., primary, Krakstad, Camilla, primary, Kupryjanczyk, Jolanta, primary, Lambrechts, Diether, primary, Lambrechts, Sandrina, primary, Le, Nhu D., primary, Lee, Alice W., primary, Lele, Shashi, primary, Leminen, Arto, primary, Lester, Jenny, primary, Levine, Douglas A., primary, Liang, Dong, primary, Lissowska, Jolanta, primary, Lu, Karen, primary, Lubinski, Jan, primary, Lundvall, Lene, primary, Massuger, Leon, primary, Matsuo, Keitaro, primary, McGuire, Valerie, primary, McLaughlin, John R., primary, McNeish, Iain A., primary, Menon, Usha, primary, Modugno, Francesmary, primary, Moysich, Kirsten B., primary, Narod, Steven A., primary, Nedergaard, Lotte, primary, Ness, Roberta B., primary, Nevanlinna, Heli, primary, Odunsi, Kunle, primary, Olson, Sara H., primary, Orlow, Irene, primary, Orsulic, Sandra, primary, Weber, Rachel Palmieri, primary, Pearce, Celeste Leigh, primary, Pejovic, Tanja, primary, Pelttari, Liisa M., primary, Permuth-Wey, Jennifer, primary, Phelan, Catherine M., primary, Pike, Malcolm C., primary, Poole, Elizabeth M., primary, Ramus, Susan J., primary, Risch, Harvey A., primary, Rosen, Barry, primary, Rossing, Mary Anne, primary, Rothstein, Joseph H., primary, Rudolph, Anja, primary, Runnebaum, Ingo B., primary, Rzepecka, Iwona K., primary, Salvesen, Helga B., primary, Schildkraut, Joellen M., primary, Schwaab, Ira, primary, Shu, Xiao-Ou, primary, Shvetsov, Yurii B., primary, Siddiqui, Nadeem, primary, Sieh, Weiva, primary, Song, Honglin, primary, Southey, Melissa C., primary, Sucheston-Campbell, Lara E., primary, Tangen, Ingvild L., primary, Teo, Soo-Hwang, primary, Terry, Kathryn L., primary, Thompson, Pamela J., primary, Timorek, Agnieszka, primary, Tsai, Ya-Yu, primary, Tworoger, Shelley S., primary, van Altena, Anne M., primary, Van Nieuwenhuysen, Els, primary, Vergote, Ignace, primary, Vierkant, Robert A., primary, Wang-Gohrke, Shan, primary, Walsh, Christine, primary, Wentzensen, Nicolas, primary, Whittemore, Alice S., primary, Wicklund, Kristine G., primary, Wilkens, Lynne R., primary, Woo, Yin-Ling, primary, Wu, Xifeng, primary, Wu, Anna, primary, Yang, Hannah, primary, Zheng, Wei, primary, Ziogas, Argyrios, primary, Sellers, Thomas A., primary, Monteiro, Alvaro N.A., primary, Freedman, Matthew L., primary, Gayther, Simon A., primary, and Pharoah, Paul D.P., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Tables S1-6, Figures S1-2 from Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk

Author

Kar, Siddhartha P., primary, Tyrer, Jonathan P., primary, Li, Qiyuan, primary, Lawrenson, Kate, primary, Aben, Katja K.H., primary, Anton-Culver, Hoda, primary, Antonenkova, Natalia, primary, Chenevix-Trench, Georgia, primary, Baker, Helen, primary, Bandera, Elisa V., primary, Bean, Yukie T., primary, Beckmann, Matthias W., primary, Berchuck, Andrew, primary, Bisogna, Maria, primary, Bjørge, Line, primary, Bogdanova, Natalia, primary, Brinton, Louise, primary, Brooks-Wilson, Angela, primary, Butzow, Ralf, primary, Campbell, Ian, primary, Carty, Karen, primary, Chang-Claude, Jenny, primary, Chen, Yian Ann, primary, Chen, Zhihua, primary, Cook, Linda S., primary, Cramer, Daniel, primary, Cunningham, Julie M., primary, Cybulski, Cezary, primary, Dansonka-Mieszkowska, Agnieszka, primary, Dennis, Joe, primary, Dicks, Ed, primary, Doherty, Jennifer A., primary, Dörk, Thilo, primary, du Bois, Andreas, primary, Dürst, Matthias, primary, Eccles, Diana, primary, Easton, Douglas F., primary, Edwards, Robert P., primary, Ekici, Arif B., primary, Fasching, Peter A., primary, Fridley, Brooke L., primary, Gao, Yu-Tang, primary, Gentry-Maharaj, Aleksandra, primary, Giles, Graham G., primary, Glasspool, Rosalind, primary, Goode, Ellen L., primary, Goodman, Marc T., primary, Grownwald, Jacek, primary, Harrington, Patricia, primary, Harter, Philipp, primary, Hein, Alexander, primary, Heitz, Florian, primary, Hildebrandt, Michelle A.T., primary, Hillemanns, Peter, primary, Hogdall, Estrid, primary, Hogdall, Claus K., primary, Hosono, Satoyo, primary, Iversen, Edwin S., primary, Jakubowska, Anna, primary, Paul, James, primary, Jensen, Allan, primary, Ji, Bu-Tian, primary, Karlan, Beth Y., primary, Kjaer, Susanne K., primary, Kelemen, Linda E., primary, Kellar, Melissa, primary, Kelley, Joseph, primary, Kiemeney, Lambertus A., primary, Krakstad, Camilla, primary, Kupryjanczyk, Jolanta, primary, Lambrechts, Diether, primary, Lambrechts, Sandrina, primary, Le, Nhu D., primary, Lee, Alice W., primary, Lele, Shashi, primary, Leminen, Arto, primary, Lester, Jenny, primary, Levine, Douglas A., primary, Liang, Dong, primary, Lissowska, Jolanta, primary, Lu, Karen, primary, Lubinski, Jan, primary, Lundvall, Lene, primary, Massuger, Leon, primary, Matsuo, Keitaro, primary, McGuire, Valerie, primary, McLaughlin, John R., primary, McNeish, Iain A., primary, Menon, Usha, primary, Modugno, Francesmary, primary, Moysich, Kirsten B., primary, Narod, Steven A., primary, Nedergaard, Lotte, primary, Ness, Roberta B., primary, Nevanlinna, Heli, primary, Odunsi, Kunle, primary, Olson, Sara H., primary, Orlow, Irene, primary, Orsulic, Sandra, primary, Weber, Rachel Palmieri, primary, Pearce, Celeste Leigh, primary, Pejovic, Tanja, primary, Pelttari, Liisa M., primary, Permuth-Wey, Jennifer, primary, Phelan, Catherine M., primary, Pike, Malcolm C., primary, Poole, Elizabeth M., primary, Ramus, Susan J., primary, Risch, Harvey A., primary, Rosen, Barry, primary, Rossing, Mary Anne, primary, Rothstein, Joseph H., primary, Rudolph, Anja, primary, Runnebaum, Ingo B., primary, Rzepecka, Iwona K., primary, Salvesen, Helga B., primary, Schildkraut, Joellen M., primary, Schwaab, Ira, primary, Shu, Xiao-Ou, primary, Shvetsov, Yurii B., primary, Siddiqui, Nadeem, primary, Sieh, Weiva, primary, Song, Honglin, primary, Southey, Melissa C., primary, Sucheston-Campbell, Lara E., primary, Tangen, Ingvild L., primary, Teo, Soo-Hwang, primary, Terry, Kathryn L., primary, Thompson, Pamela J., primary, Timorek, Agnieszka, primary, Tsai, Ya-Yu, primary, Tworoger, Shelley S., primary, van Altena, Anne M., primary, Van Nieuwenhuysen, Els, primary, Vergote, Ignace, primary, Vierkant, Robert A., primary, Wang-Gohrke, Shan, primary, Walsh, Christine, primary, Wentzensen, Nicolas, primary, Whittemore, Alice S., primary, Wicklund, Kristine G., primary, Wilkens, Lynne R., primary, Woo, Yin-Ling, primary, Wu, Xifeng, primary, Wu, Anna, primary, Yang, Hannah, primary, Zheng, Wei, primary, Ziogas, Argyrios, primary, Sellers, Thomas A., primary, Monteiro, Alvaro N.A., primary, Freedman, Matthew L., primary, Gayther, Simon A., primary, and Pharoah, Paul D.P., primary

Published
2023
Full Text
View/download PDF

44. Primary Treatment Effects for High-Grade Serous Ovarian Carcinoma Evaluated by Changes in Serum Metabolites and Lipoproteins

Author

Torkildsen, Cecilie Fredvik, primary, Austdal, Marie, additional, Iversen, Ann-Charlotte, additional, Bathen, Tone Frost, additional, Giskeødegård, Guro Fanneløb, additional, Nilsen, Elisabeth Berge, additional, Iversen, Grete Alræk, additional, Sande, Ragnar Kvie, additional, Bjørge, Line, additional, and Thomsen, Liv Cecilie Vestrheim, additional

Published
2023
Full Text
View/download PDF

46. Combining Mass Cytometry Data by CyTOFmerge Reveals Additional Cell Phenotypes in the Heterogeneous Ovarian Cancer Tumor Microenvironment: A Pilot Study

Author

Thomsen, L.C.V. (author), Kleinmanns, Katrin (author), Anandan, Shamundeeswari (author), Gullaksen, Stein Erik (author), Abdelaal, T.R.M. (author), Iversen, Grete Alrek (author), Akslen, Lars Andreas (author), McCormack, Emmet (author), Bjørge, Line (author), Thomsen, L.C.V. (author), Kleinmanns, Katrin (author), Anandan, Shamundeeswari (author), Gullaksen, Stein Erik (author), Abdelaal, T.R.M. (author), Iversen, Grete Alrek (author), Akslen, Lars Andreas (author), McCormack, Emmet (author), and Bjørge, Line (author)

Abstract

The prognosis of high-grade serous ovarian carcinoma (HGSOC) is poor, and treatment selection is challenging. A heterogeneous tumor microenvironment (TME) characterizes HGSOC and influences tumor growth, progression, and therapy response. Better characterization with multidimensional approaches for simultaneous identification and categorization of the various cell populations is needed to map the TME complexity. While mass cytometry allows the simultaneous detection of around 40 proteins, the CyTOFmerge MATLAB algorithm integrates data sets and extends the phenotyping. This pilot study explored the potential of combining two datasets for improved TME phenotyping by profiling single-cell suspensions from ten chemo-naïve HGSOC tumors by mass cytometry. A 35-marker pan-tumor dataset and a 34-marker pan-immune dataset were analyzed separately and combined with the CyTOFmerge, merging 18 shared markers. While the merged analysis confirmed heterogeneity across patients, it also identified a main tumor cell subset, additionally to the nine identified by the pan-tumor panel. Furthermore, the expression of traditional immune cell markers on tumor and stromal cells was revealed, as were marker combinations that have rarely been examined on individual cells. This study demonstrates the potential of merging mass cytometry data to generate new hypotheses on tumor biology and predictive biomarker research in HGSOC that could improve treatment effectiveness., Pattern Recognition and Bioinformatics

Published
2023
Full Text
View/download PDF

47. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

Author

Hollestelle, Antoinette, van der Baan, Frederieke H., Berchuck, Andrew, Johnatty, Sharon E., Aben, Katja K., Agnarsson, Bjarni A., Aittomäki, Kristiina, Alducci, Elisa, Andrulis, Irene L., Anton-Culver, Hoda, Antonenkova, Natalia N., Antoniou, Antonis C., Apicella, Carmel, Arndt, Volker, Arnold, Norbert, Arun, Banu K., Arver, Brita, Ashworth, Alan, Baglietto, Laura, Balleine, Rosemary, Bandera, Elisa V., Barrowdale, Daniel, Bean, Yukie T., Beckmann, Lars, Beckmann, Matthias W., Benitez, Javier, Berger, Andreas, Berger, Raanan, Beuselinck, Benoit, Bisogna, Maria, Bjorge, Line, Blomqvist, Carl, Bogdanova, Natalia V., Bojesen, Anders, Bojesen, Stig E., Bolla, Manjeet K., Bonanni, Bernardo, Brand, Judith S., Brauch, Hiltrud, Brenner, Hermann, Brinton, Louise, Brooks-Wilson, Angela, Bruinsma, Fiona, Brunet, Joan, Brüning, Thomas, Budzilowska, Agnieszka, Bunker, Clareann H., Burwinkel, Barbara, Butzow, Ralf, Buys, Saundra S., Caligo, Maria A., Campbell, Ian, Carter, Jonathan, Chang-Claude, Jenny, Chanock, Stephen J., Claes, Kathleen B.M., Collée, J. Margriet, Cook, Linda S., Couch, Fergus J., Cox, Angela, Cramer, Daniel, Cross, Simon S., Cunningham, Julie M., Cybulski, Cezary, Czene, Kamila, Damiola, Francesca, Dansonka-Mieszkowska, Agnieszka, Darabi, Hatef, de la Hoya, Miguel, deFazio, Anna, Dennis, Joseph, Devilee, Peter, Dicks, Ed M., Diez, Orland, Doherty, Jennifer A., Domchek, Susan M., Dorfling, Cecilia M., Dörk, Thilo, Silva, Isabel Dos Santos, du Bois, Andreas, Dumont, Martine, Dunning, Alison M., Duran, Mercedes, Easton, Douglas F., Eccles, Diana, Edwards, Robert P., Ehrencrona, Hans, Ejlertsen, Bent, Ekici, Arif B., Ellis, Steve D., Engel, Christoph, Eriksson, Mikael, Fasching, Peter A., Feliubadalo, Lidia, Figueroa, Jonine, Flesch-Janys, Dieter, Fletcher, Olivia, Fontaine, Annette, Fortuzzi, Stefano, Fostira, Florentia, Fridley, Brooke L., Friebel, Tara, Friedman, Eitan, Friel, Grace, Frost, Debra, Garber, Judy, García-Closas, Montserrat, Gayther, Simon A., Gentry-Maharaj, Aleksandra, Gerdes, Anne-Marie, Giles, Graham G., Glasspool, Rosalind, Glendon, Gord, Godwin, Andrew K., Goodman, Marc T., Gore, Martin, Greene, Mark H., Grip, Mervi, Gronwald, Jacek, Gschwantler Kaulich, Daphne, Guénel, Pascal, Guzman, Starr R., Haeberle, Lothar, Haiman, Christopher A., Hall, Per, Halverson, Sandra L., Hamann, Ute, Hansen, Thomas V.O., Harter, Philipp, Hartikainen, Jaana M., Healey, Sue, Hein, Alexander, Heitz, Florian, Henderson, Brian E., Herzog, Josef, T Hildebrandt, Michelle A., Høgdall, Claus K., Høgdall, Estrid, Hogervorst, Frans B.L., Hopper, John L., Humphreys, Keith, Huzarski, Tomasz, Imyanitov, Evgeny N., Isaacs, Claudine, Jakubowska, Anna, Janavicius, Ramunas, Jaworska, Katarzyna, Jensen, Allan, Jensen, Uffe Birk, Johnson, Nichola, Jukkola-Vuorinen, Arja, Kabisch, Maria, Karlan, Beth Y., Kataja, Vesa, Kauff, Noah, Kelemen, Linda E., Kerin, Michael J., Kiemeney, Lambertus A., Kjaer, Susanne K., Knight, Julia A., Knol-Bout, Jacoba P., Konstantopoulou, Irene, Kosma, Veli-Matti, Krakstad, Camilla, Kristensen, Vessela, Kuchenbaecker, Karoline B., Kupryjanczyk, Jolanta, Laitman, Yael, Lambrechts, Diether, Lambrechts, Sandrina, Larson, Melissa C., Lasa, Adriana, Laurent-Puig, Pierre, Lazaro, Conxi, Le, Nhu D., Le Marchand, Loic, Leminen, Arto, Lester, Jenny, Levine, Douglas A., Li, Jingmei, Liang, Dong, Lindblom, Annika, Lindor, Noralane, Lissowska, Jolanta, Long, Jirong, Lu, Karen H., Lubinski, Jan, Lundvall, Lene, Lurie, Galina, Mai, Phuong L., Mannermaa, Arto, Margolin, Sara, Mariette, Frederique, Marme, Frederik, Martens, John W.M., Massuger, Leon F.A.G., Maugard, Christine, Mazoyer, Sylvie, McGuffog, Lesley, McGuire, Valerie, McLean, Catriona, McNeish, Iain, Meindl, Alfons, Menegaux, Florence, Menéndez, Primitiva, Menkiszak, Janusz, Menon, Usha, Mensenkamp, Arjen R., Miller, Nicola, Milne, Roger L., Modugno, Francesmary, Montagna, Marco, Moysich, Kirsten B., Müller, Heiko, Mulligan, Anna Marie, Muranen, Taru A., Narod, Steven A., Nathanson, Katherine L., Ness, Roberta B., Neuhausen, Susan L., Nevanlinna, Heli, Neven, Patrick, Nielsen, Finn C., Nielsen, Sune F., Nordestgaard, Børge G., Nussbaum, Robert L., Odunsi, Kunle, Offit, Kenneth, Olah, Edith, Olopade, Olufunmilayo I., Olson, Janet E., Olson, Sara H., Oosterwijk, Jan C., Orlow, Irene, Orr, Nick, Orsulic, Sandra, Osorio, Ana, Ottini, Laura, Paul, James, Pearce, Celeste L., Pedersen, Inge Sokilde, Peissel, Bernard, Pejovic, Tanja, Pelttari, Liisa M., Perkins, Jo, Permuth-Wey, Jenny, Peterlongo, Paolo, Peto, Julian, Phelan, Catherine M., Phillips, Kelly-Anne, Piedmonte, Marion, Pike, Malcolm C., Platte, Radka, Plisiecka-Halasa, Joanna, Poole, Elizabeth M., Poppe, Bruce, Pylkäs, Katri, Radice, Paolo, Ramus, Susan J., Rebbeck, Timothy R., Reed, Malcolm W.R., Rennert, Gad, Risch, Harvey A., Robson, Mark, Rodriguez, Gustavo C., Romero, Atocha, Rossing, Mary Anne, Rothstein, Joseph H., Rudolph, Anja, Runnebaum, Ingo, Salani, Ritu, Salvesen, Helga B., Sawyer, Elinor J., Schildkraut, Joellen M., Schmidt, Marjanka K., Schmutzler, Rita K., Schneeweiss, Andreas, Schoemaker, Minouk J., Schrauder, Michael G., Schumacher, Fredrick, Schwaab, Ira, Scuvera, Giulietta, Sellers, Thomas A., Severi, Gianluca, Seynaeve, Caroline M., Shah, Mitul, Shrubsole, Martha, Siddiqui, Nadeem, Sieh, Weiva, Simard, Jacques, Singer, Christian F., Sinilnikova, Olga M., Smeets, Dominiek, Sohn, Christof, Soller, Maria, Song, Honglin, Soucy, Penny, Southey, Melissa C., Stegmaier, Christa, Stoppa-Lyonnet, Dominique, Sucheston, Lara, Swerdlow, Anthony, Tangen, Ingvild L., Tea, Muy-Kheng, Teixeira, Manuel R., Terry, Kathryn L., Terry, Mary Beth, Thomassen, Mads, Thompson, Pamela J., Tihomirova, Laima, Tischkowitz, Marc, Toland, Amanda Ewart, Tollenaar, Rob A.E.M., Tomlinson, Ian, Torres, Diana, Truong, Thérèse, Tsimiklis, Helen, Tung, Nadine, Tworoger, Shelley S., Tyrer, Jonathan P., Vachon, Celine M., Van 't Veer, Laura J., van Altena, Anne M., Van Asperen, C.J., van den Berg, David, van den Ouweland, Ans M.W., van Doorn, Helena C., Van Nieuwenhuysen, Els, van Rensburg, Elizabeth J., Vergote, Ignace, Verhoef, Senno, Vierkant, Robert A., Vijai, Joseph, Vitonis, Allison F., von Wachenfeldt, Anna, Walsh, Christine, Wang, Qin, Wang-Gohrke, Shan, Wappenschmidt, Barbara, Weischer, Maren, Weitzel, Jeffrey N., Weltens, Caroline, Wentzensen, Nicolas, Whittemore, Alice S., Wilkens, Lynne R., Winqvist, Robert, Wu, Anna H., Wu, Xifeng, Yang, Hannah P., Zaffaroni, Daniela, Pilar Zamora, M., Zheng, Wei, Ziogas, Argyrios, Chenevix-Trench, Georgia, Pharoah, Paul D.P., Rookus, Matti A., Hooning, Maartje J., and Goode, Ellen L.

Published
2016
Full Text
View/download PDF

48. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

Author

du Bois, Andreas, Kristensen, Gunnar, Ray-Coquard, Isabelle, Reuss, Alexander, Pignata, Sandro, Colombo, Nicoletta, Denison, Ursula, Vergote, Ignace, del Campo, Jose M, Ottevanger, Petronella, Heubner, Martin, Minarik, Thomas, Sevin, Emmanuel, de Gregorio, Nikolaus, Bidziński, Mariusz, Pfisterer, Jacobus, Malander, Susanne, Hilpert, Felix, Mirza, Mansoor R, Scambia, Giovanni, Meier, Werner, Nicoletto, Maria O, Bjørge, Line, Lortholary, Alain, Sailer, Martin Oliver, Merger, Michael, and Harter, Philipp

Published
2016
Full Text
View/download PDF

50. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Author

Oaknin, Ana, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Nishio, Shin, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Yamaguchi, Satoshi, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, D'Hondt, Véronique, Randall, Leslie M, Abadie-Lacourtoisie, Sophie, Andreetta, Claudia, Anzizar, Nerea, Aoki, Daiseuke, Barretina-Ginesta, Maria-Pilar, Battista, Marco, Bellier, Charlotte, Bentzen, Anne Gry, Berton, Dominique, Billemont, Bertrand, Bjørge, Line, Bjurberg, Maria, Black, Destin, Bologna, Alessandra, Braicu, Elena Ioana, Casanova, Claudia, Chekerov, Radoslav, Chevalier, Annick, Cueva, Juan Fernando, Czogalla, Bastian, Delanoy, Nicolas, Denschlag, Dominik, Derke, Oscar, Eichbaum, Michael, Enomoto, Takayuki, Esteban, Carmen, Fabbro, Michel, Fehm, Tanja, Ferrero, Annamaria, Fleisch, Markus, Floquet, Anne, Frassoldati, Antonio, Gaba, Lydia, Gadducci, Angiolo, García, Yolanda, Geuna, Elena, Guerra, Eva, Hanker, Lars, Hardy-Bessard, Anne-Claire, Harter, Philipp, Hasegawa, Kosei, Hellman, Kristina, Herrero, Ana, Hilpert, Felix, Katsaros, Dionyssios, Koegel, Matthias, Koliadi, Anthoula, Kurtz, Jean-Emmanuel, Lampe, Bjoern, Lissoni, Andrea Alberto, Lortholary, Alain, Mangili, Giorgia, Mansi, Laura, Marmé, Frederik, Mathews, Cara, Mina, William, Minobe, Shinichiro, Moxley, Katherine, Nagao, Shoji, Nicoletto, Ornella, Nishino, Koji, Nishio, Hiroshi, Nishio, Shin, Oaknin, Ana, Onstad, Michaela, Pardo, Beatriz, Pérez-Fidalgo, J Alejandro, Pisano, Carmela, Poveda, Andrés, Radosa, Julia, Randall, Leslie M., Ray-Coquard, Isabelle, Redondo, Andrés, Richardson, Debra, Romero, Ignacio, Ronzino, Graziana, Rubio, Maria Jesús, Selle, Frederic, Takekuma, Munetaka, Takeshima, Nobuhiro, Tasca, Giulia, Tewari, Krishnansu, Todo, Yukiharu, Valabrega, Giorgio, Wimberger, Pauline, Woelber, Linn, Yamaguchi, Satoshi, You, Benoît, and Yunokawa, Mayu

Abstract

The GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030), we aimed to evaluate the addition of an immune checkpoint inhibitor to this standard backbone.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results